Moderna, Inc. (NASDAQ: MRNA) announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026, according to a company press release. McDonnell will also serve on the Board's Audit Committee.

McDonnell most recently served as Executive Vice President and Chief Financial Officer of Biogen Inc. from August 2020 through February 2025. Since March 2025, he has served as an advisor to Goldman Sachs Asset Management.

Prior to Biogen, McDonnell held CFO roles at IQVIA Holdings Inc., Intelsat S.A., MCG Capital Corporation, and EchoStar Communications Corporation. He began his career at PricewaterhouseCoopers LLP, where he spent 14 years, including four years as a partner. In total, he has more than 24 years of experience as CFO of public companies.

McDonnell currently serves on the boards of Merit Medical Systems, Inc., where he chairs the Audit Committee, and Baxter International Inc.

Noubar Afeyan, Co-Founder and Chairman of Moderna, said McDonnell's "experience guiding organizations through periods of growth and transformation, overseeing significant capital allocation decisions, and building high-performing finance organizations will be invaluable as Moderna continues to advance its pipeline and execute on its long-term strategy."